Hengrui Pharmaceutical announced that the company and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the HRS-4729 injection “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to carry out phase II clinical trials for chronic kidney disease. HRS-4729 injection is a GLP-1R/GIPR/GCGR triagonist polypeptide drug independently developed by the company. Currently, no similar drug has been approved for marketing at home or abroad. Up to now, the project has invested about 87.6 million yuan in R&D.

Hengrui Pharmaceutical announced that the company and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the HRS-4729 injection “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to carry out phase II clinical trials for chronic kidney disease. HRS-4729 injection is a GLP-1R/GIPR/GCGR triagonist polypeptide drug independently developed by the company. Currently, no similar drug has been approved for marketing at home or abroad. Up to now, the project has invested about 87.6 million yuan in R&D.